Abstract 2364
Background
KEYNOTE-181 (NCT02564263) is an open-label, randomized, phase 3 trial of pembrolizumab (P) vs investigator’s choice of single-agent paclitaxel, docetaxel, or irinotecan (standard of care [SOC]) in advanced/metastatic AC or SCC of the esophagus. In the global cohort, P was superior to SOC for OS in pts with PD-L1 combined positive score (CPS) ≥10, with a more favorable safety profile. We present results of the China cohort.
Methods
Eligible pts were randomly assigned 1:1 to receive P 200 mg Q3W for up to 2 y or investigator’s choice of SOC. Randomization was stratified by histology (SCC vs AC) and region (Asia vs rest of world). Primary end points were OS in the intention-to-treat (ITT), SCC, and PD-L1 CPS ≥10 populations.
Results
Of the 123 Chinese pts enrolled, 119 had SCC and 54 had CPS ≥10. Pts were randomly assigned to receive P (62 pts; 60 had SCC; 25 had CPS ≥10) or SOC (61 pts; 59 had SCC; 29 had CPS ≥10). As of Feb 13, 2019, the median follow-up (from randomization, regardless of death) was 15.1 mo (P) vs 14.7 mo (SOC). Median OS was longer with P vs SOC overall (8.4 vs 5.6 mo; HR 0.55; 95% CI 0.36-0.82) and in the SCC (8.4 vs 5.6 mo; HR 0.55; 95% CI 0.37-0.83), and CPS ≥10 groups (12.0 vs 5.3 mo; HR 0.34; 95% CI 0.17-0.69). Median OS for P vs SOC in the CPS <10 group was 6.4 vs 6.1 mo (HR 0.72; 95% 0.43-1.21). OS rates at 12 mo for the P vs SOC groups were 36.3% vs 16.7% overall, 35.7% vs 15.3% in the SCC, and 53.1% vs 16.1% in the CPS ≥10 groups. PFS rates at 6 mo were similar for P vs SOC (26.4% vs 24.1% in the ITT group), but ORR was substantially higher (16.1% vs 3.3% in the ITT group). Median DOR was not reached for P (4.4+ to 14.6+ mo) and was 3.2 mo (2.6-3.9) for the SOC group. Fewer pts receiving P vs SOC had any-grade (76% vs 83%) or grade 3-5 (21% vs 42%) drug-related AEs or drug-related AEs that resulted in discontinuation (6.4% vs 11.9%).
Conclusions
P showed favorable OS, compared with SOC, as second-line therapy for AC/SCC in Chinese pts, with a more favorable safety profile. In China, more patients had SCC than AC and P showed clinically meaningful OS improvement regardless of PD-L1 status. This finding was consistent with that of the Asia group from the full global cohort.
Clinical trial identification
NCT02564263, September 30, 2015.
Editorial acknowledgement
Amy McQuay, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA), funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
J. Zhang: Advisory / Consultancy: Bayer; Advisory / Consultancy: BMS; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Merck-Serono; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Taiho; Speaker Bureau / Expert testimony: HengRui; Speaker Bureau / Expert testimony: Novartis. Y. Cui: Full / Part-time employment: MSD, China. P. Bhagia: Full / Part-time employment: Merck & Co., Inc. S.P. Kang: Full / Part-time employment: Merck & Co., Inc.; Shareholder / Stockholder / Stock options: Celgene; Shareholder / Stockholder / Stock options: Macrogenics; Shareholder / Stockholder / Stock options: Celldex; Shareholder / Stockholder / Stock options: Agenus; Shareholder / Stockholder / Stock options: Pharmacyclics; Shareholder / Stockholder / Stock options: Endocyte. W. Lu: Full / Part-time employment: MSD, China. Y. Zhou: Full / Part-time employment: MSD China. All other authors have declared no conflicts of interest.
Resources from the same session
5203 - Novel fusion genes identified from matched primary and recurred breast cancers by RNA-sequencing
Presenter: Soojeong Choi
Session: Poster Display session 2
Resources:
Abstract
5873 - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
Presenter: Donna Fitzgerald
Session: Poster Display session 2
Resources:
Abstract
3588 - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: a translational approach.
Presenter: Anna Adam-Artigues
Session: Poster Display session 2
Resources:
Abstract
5640 - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
Presenter: Marija Balic
Session: Poster Display session 2
Resources:
Abstract
2616 - Clinical application of mutational analysis in breast cancer patients: the relevance of PIK3CA analysis for precision medicine.
Presenter: Juan Miguel Cejalvo
Session: Poster Display session 2
Resources:
Abstract
3870 - A retrospective gene expression analysis of surgically-removed Breast Cancer Brain Metastasis (BCBM)
Presenter: Meritxell Mallafré-Larrosa
Session: Poster Display session 2
Resources:
Abstract
1240 - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: meta-analysis of Phase II and III randomized clinical trials
Presenter: Claudia Omarini
Session: Poster Display session 2
Resources:
Abstract
5535 - Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): management and time course of key adverse events of special interest (AESIs) in SOLAR-1
Presenter: Hope Rugo
Session: Poster Display session 2
Resources:
Abstract
3093 - Changes in Hormone-Receptor status in Luminal breast cancers between primary tumor and metastases: results of the observational cohort GIM-13 AMBRA Study
Presenter: Marina Cazzaniga
Session: Poster Display session 2
Resources:
Abstract
1378 - MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
Presenter: Miguel Martín
Session: Poster Display session 2
Resources:
Abstract